微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 31.06% | -0.13% | -1.9% | 113/159 | -2.82% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 31.66% | -0.58% | 0.97% | 112/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 31.35% | -4.07% | 0.59% | 112/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 31.17% | -2.88% | 0.23% | 119/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 31.1% | -7.92% | -2.34% | 117/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 31.84% | -11.61% | -2.57% | 116/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 32.68% | -12.85% | 1.83% | 113/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 32.09% | -10.3% | -4.97% | 116/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 33.77% | -3.67% | -6.25% | 109/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 36.02% | -2.46% | -3.94% | 110/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 37.5% | -3.5% | 4.81% | 105/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 35.78% | -5.55% | 2.05% | 111/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 35.06% | -11.38% | -5.06% | 105/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 36.93% | -13.06% | -4.97% | 109/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 38.86% | -16.46% | 2.58% | 97/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 37.88% | -25.07% | -4.25% | 112/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 39.56% | -17.21% | -6.86% | 94/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 42.48% | -10.53% | -8.68% | 93/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 46.52% | 2.49% | -7.99% | 74/159 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 50.56% | 41.22% | 5.79% | 79/159 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 47.79% | 26.3% | 0.66% | 74/159 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 47.47% | 23.58% | 4.6% | 80/159 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 45.38% | 17.85% | 26.77% | 72/159 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 35.8% | -19.9% | -5.38% | 108/159 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 37.84% | -18.18% | -1.5% | 81/159 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 38.41% | -18.74% | -0.25% | 84/159 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 38.51% | -21.4% | -13.83% | 78/159 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 44.69% | -0.73% | -3.36% | 81/159 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 46.25% | 10.6% | -2.17% | 61/159 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 47.27% | 15.2% | -3.52% | 62/159 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 49% | 27.17% | 8.83% | 56/159 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 45.02% | 12.91% | 7.66% | 72/159 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 41.82% | 5.65% | 1.9% | 56/159 | 49% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 41.04% | 6.28% | 6.51% | 60/159 | 47.74% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 38.53% | 1.85% | -3.37% | 52/159 | 46.55% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 39.87% | -2.99% | 0.74% | 69/159 | 48.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 39.58% | -11.96% | 2.52% | 46/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 38.61% | -15.79% | 2.07% | 54/159 | 45.89% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 37.83% | -10.88% | -7.96% | 45/159 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 41.1% | 7.22% | -8.58% | 56/159 | 45.97% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 44.96% | 23% | -1.95% | 36/159 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 45.85% | 30.85% | 8.03% | 38/159 | 45% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 42.44% | 19.11% | 10.72% | 38/159 | 43.46% | 舒泰神 | 94.4% | 行业排名> |